Beta Bionics Announces Closing of a $63 Million Series B2 Financing, Bringing the Total Series B and B2 Financings to $126 Million •The round was co-led by new investors Perceptive Advisors and Soleus Capital •New investor Farallon Capital also participated in the round, as did previous Series B investors RTW Investments, ArrowMark Partners and funds managed by Eventide Asset Management •Funds will support final product development, regulatory submission and commercial launch of the iLet TM Bionic Pancreas System Contact: Company Contacts Ed Damiano edamiano@betabionics.com Ed Raskin eraskin@betabionics.com Investor Relations Contact Jeremy Feffer jeremy@lifesciadvisors.com.